First quarter 2025 financial results and status for Medistim ASA

09 May 2025 08:00 CEST

An exceptionally strong quarter for sales revenues, 20.1 % above the previous
record, ending at MNOK 181.5. This is growth of 35.7 % compared to first quarter
last year (MNOK 133.8).

Currency neutral sales of own products were up 29.9 % for the quarter.

Strong growth in all geographies with AMERICAS up 28.4 %, EMEA up 18.2 % and
APAC up 62.6 %, currency neutral.

Third-party distributor sales in Scandinavia increased 41.2 % for the quarter.

Operating profit (EBIT) grew by 84.5 % and ended at MNOK 59.2 giving a 32.6 %
EBIT margin (MNOK 32.1, 24.0 % margin)

Recurring sales remained high, but strong capital sales reduce recurring sales
in percent to 68 % (75 %) compared to same quarter last year.

Medistim strengthened its commercial operation by appointing a Chief Commercial
Officer and a new VP Sales for AMERICAS.

Solid cash position at quarter end with MNOK 183.4 and no interest-bearing
liabilities.
The General Meeting decided a dividend of NOK 6.00 per share (NOK 4.5), total
MNOK 109.6 (MNOK 82.4).

More information:
Access the news on Oslo Bors NewsWeb site

645879_Q1 2025 Report-Final_08.05.25.pdf
645879_Q1 2025 PPT presentation.pdf